- Home
- REVB vs SXTC Comparison
REVB vs SXTC Comparison
Compare REVB & SXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- SXTC
- Stock Information
- Founded
- REVB 2020
- SXTC 2005
- Country
- REVB United States
- SXTC China
- Employees
- REVB N/A
- SXTC N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- SXTC Biotechnology: Pharmaceutical Preparations
- Sector
- REVB Health Care
- SXTC Health Care
- Exchange
- REVB Nasdaq
- SXTC Nasdaq
- Market Cap
- REVB 3.1M
- SXTC 2.5M
- IPO Year
- REVB N/A
- SXTC 2019
- Fundamental
- Price
- REVB $0.80
- SXTC $0.39
- Analyst Decision
- REVB
- SXTC
- Analyst Count
- REVB 0
- SXTC 0
- Target Price
- REVB N/A
- SXTC N/A
- AVG Volume (30 Days)
- REVB 1.3M
- SXTC 206.0K
- Earning Date
- REVB 11-08-2024
- SXTC 01-01-0001
- Dividend Yield
- REVB N/A
- SXTC N/A
- EPS Growth
- REVB N/A
- SXTC N/A
- EPS
- REVB N/A
- SXTC N/A
- Revenue
- REVB N/A
- SXTC $1,928,497.00
- Revenue This Year
- REVB N/A
- SXTC N/A
- Revenue Next Year
- REVB N/A
- SXTC N/A
- P/E Ratio
- REVB N/A
- SXTC N/A
- Revenue Growth
- REVB N/A
- SXTC N/A
- 52 Week Low
- REVB $0.70
- SXTC $0.37
- 52 Week High
- REVB $25.26
- SXTC $6.39
- Technical
- Relative Strength Index (RSI)
- REVB 44.03
- SXTC 29.34
- Support Level
- REVB $0.80
- SXTC $0.45
- Resistance Level
- REVB $1.05
- SXTC $0.51
- Average True Range (ATR)
- REVB 0.07
- SXTC 0.06
- MACD
- REVB -0.00
- SXTC -0.01
- Stochastic Oscillator
- REVB 9.69
- SXTC 5.97
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About SXTC China SXT Pharmaceuticals Inc.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.